Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Surgical Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- What's new in genetic testing for cancer susceptibility?.Oncology (Williston Park). 2016; 30: 787-799
- Baby's first test: conditions screened by state. Baby's first test.(Available at:) (Accessed June 9, 2021)
- Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome.JAMA Oncol. 2021; 7: 230-237
- Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis.BMJ. 2014; 348: g226
- Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers.Breast Cancer Res Treat. 2019; 177: 723-733
- Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.J Clin Oncol. 2014; 32: 1547-1553
- Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database.Gut. 2017; 66: 464-472
- Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US Preventive Services Task Force Recommendation Statement.JAMA. 2019; 322: 652-665
- Genetic/Familial high-risk assessment: breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw. 2021; 19: 77-102
- American society of clinical oncology policy statement update: genetic and genomic testing for cancer susceptibility.J Clin Oncol. 2015; 33: 3660-3667
- Consensus guidelines on genetic` testing for hereditary breast cancer from the American Society of Breast Surgeons.Ann Surg Oncol. 2019; 26: 3025-3031
- Committee opinion No. 693: counseling about genetic testing and communication of genetic test results.Obstet Gynecol. 2017; 129: e96-e101
- Practice bulletin no. 182 summary: hereditary breast and ovarian cancer syndrome.Obstet Gynecol. 2017; 130: 657-659
- Cancer screening and genetic testing recommendations for relatives of men undergoing prostate cancer germline testing: implications for practice.J Urol. 2020; 204: 1116-1118
- ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.Am J Gastroenterol. 2015; 110 ([quiz 263]): 223-262
- Points to consider: is there evidence to support BRCA1/2 and other inherited breast cancer genetic testingfor all breast cancer patients? A statement of the American College of Medical Geneticsand Genomics (ACMG).Genet Med. 2020; 22: 681-685
- Racial and ethnic disparities in genetic testing at a hereditary breast and ovarian cancer center.J Gen Intern Med. 2021; 36: 35-42
- Oncologists' opinions on genetic testing for breast and ovarian cancer.Genet Med. 2001; 3: 120-125
- Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award.JAMA. 2014; 312: 1091-1092
- Differential use of available genetic tests among primary care physicians in the United States: results of a national survey.Genet Med. 2008; 10: 404-414
- The primary care physician role in cancer genetics: a qualitative study of patient experience.Fam Pract. 2010; 27: 563-569
- ACOG Committee Opinion No. 442: Preconception and prenatal carrier screening for genetic diseases in individuals of Eastern European Jewish descent.Obstet Gynecol. 2009; 114: 950
- Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk.Genet Med. 2018; 20: 234-239
- A high frequency of BRCA mutations in young black women with breast cancer residing in Florida.Cancer. 2015; 121: 4173-4180
- Racial and ethnic differences in BRCA1/2 and multigene panel testing among young breast cancer patients.J Cancer Educ. 2021 Jun; 36: 463-469https://doi.org/10.1007/s13187-019-01646-8
- Racial and ethnic differences in multigene hereditary cancer panel test results for women with breast cancer.J Natl Cancer Inst. 2020 Nov 4; djaa167https://doi.org/10.1093/jnci/djaa167
- Analysis of protein-coding genetic variation in 60,706 humans.Nature. 2016; 536: 285-291
- BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer.Cancer. 2009; 115: 2222-2233
- Gaps in incorporating germline genetic testing into treatment decision-making for early-stage breast cancer.J Clin Oncol. 2017; 35: 2232-2239
- A comprehensive laboratory-based program for classification of variants of uncertain significance in hereditary cancer genes.Clin Genet. 2014; 86: 229-237
- Germline genetic testing: what the breast surgeon needs to know.Ann Surg Oncol. 2019 Jul; 26: 2184-2190https://doi.org/10.1245/s10434-019-07341-8
- Smedley B.D. Stith A.Y. Nelson A.R. Unequal treatment: confronting racial and ethnic disparities in health care. National Academies Press (US) Copyright 2002 by the National Academy of Sciences, Washington (DC)2003
- Cancer disparities. NIH: National Cancer Institute, 2020 (Available at:) (Accessed March 31, 2021)
Cancer facts and figures 2020. 2020. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf. Accessed March 31, 2021.
- The association between health literacy and cancer-related attitudes, behaviors, and knowledge.J Health Commun. 2013; 18: 223-241
- Barriers to the use of genetic testing: a study of racial and ethnic disparities.Genet Med. 2009; 11: 655-662
- Bias in the reporting of family history: implications for clinical care.J Genet Couns. 2012; 21: 547-556
- Racial and gender disparities in hereditary colorectal cancer risk assessment: the role of family history.J Cancer Educ. 2006; 21: S32-S36
- BreastCancer.Org.(Available at:) (Accessed March 31, 2021)
- Using genetic technologies to reduce, rather than widen, health disparities.Health Aff (Project Hope). 2016; 35: 1367-1373
- Genetic test availability and spending: where are we now? where are we going?.Health Aff (Project Hope). 2018; 37: 710-716
- Disparities in BRCA testing: when insurance coverage is not a barrier.Am J Surg. 2009; 198: 562-565
- Knowledge, attitudes, and perceived barriers towards genetic testing across three rural Illinois communities.J Community Genet. 2019; 10: 417-423
- Videoconferencing to deliver genetics services: a systematic review of telegenetics in light of the COVID-19 pandemic.Genet Med. 2021; : 1-12
- Racial and ethnic disparities in awareness of cancer genetic testing among online users: internet use, health knowledge, and socio-demographic correlates.J Consumer Health Internet. 2014; 18: 15-30
- Racial and ethnic variations in knowledge and attitudes about genetic testing.Genet Test. 2004; 8: 31-43
- The need to build trust: a perspective on disparities in genetic testing.Genet Test Mol Biomarkers. 2013; 17: 647-648
- Cancer statistics, 2020.CA Cancer J Clin. 2020; 70: 7-30
- Germline genetic testing for breast cancer risk: the past, present, and future.Am Soc Clin Oncol Educ Book. 2019; 39: 61-74
- A population-based study of genes previously implicated in breast cancer.N Engl J Med. 2021; 384: 440-451
- NCCN guidelines: breast cancer screening and diagnosis (version 1.2020).(Available at:)https://www.nccn.org/professionals/physician_gls/pdf/breast-screening.pdf(Accessed December 30, 2020)Date: 2020
- Prophylactic mastectomy for the prevention of breast cancer: Review of the literature.Avicenna J Med. 2018; 8: 67-77
- Risk-reducing mastectomy for the prevention of primary breast cancer.Cochrane Database Syst Rev. 2018; 4 (Cd002748)
- Olaparib for metastatic breast cancer in patients with a germline BRCA mutation.N Engl J Med. 2017; 377: 523-533
- Talazoparib in patients with advanced breast cancer and a germline BRCA mutation.N Engl J Med. 2018; 379: 753-763
- Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer.N Engl J Med. 2021 Jun 24; 384: 2394-2405https://doi.org/10.1056/NEJMoa2105215
- Racial disparities in breast cancer hereditary risk assessment referrals.J Genet Couns. 2020; 29: 587-593
- Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors.Cancer. 2017; 123: 2497-2505
- Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients.J Clin Oncol. 2019; 37: 1305-1315
- Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.J Clin Oncol. 2008; 26: 1093-1097
- Disparities in gynecologic cancer genetics evaluation.Gynecol Oncol. 2019; 153: 184-191
- Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities.Obstet Gynecol. 2010; 115: 945-952
- Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1/2 mutation (SOLO3): a randomized phase III trial.J Clin Oncol. 2020; 38: 1164-1174
- Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer.N Engl J Med. 2018; 379: 2495-2505
- Endometrial cancer: a review and current management strategies: part I.Gynecol Oncol. 2014; 134: 385-392
Henley SJ, Miller JW, Dowling NF, et al. Uterine cancer incidence and mortality — United States, 1999–2016. 2018 Dec 7;67(48):1333–38. https://doi.org/10.15585/mmwr.mm6748a1.
- PTEN: one gene, many syndromes.Hum Mutat. 2003; 22: 183-198
- Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals.Gynecol Oncol. 2015; 138: 109-114
Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2012, National Cancer Institute. Bethesda, MD. Available at: http://seer.cancer.gov/csr/1975_2012/. Accessed March 1, 2021.
- Ethnic disparities among men with prostate cancer undergoing germline testing.Urol Oncol. 2020; 38: 80.e81-80.e87
- Disparities in precision medicine-examining germline genetic counseling and testing patterns among men with prostate cancer.Urol Oncol. 2021; 39 (233.e9–233.e14)
- Olaparib for metastatic castration-resistant prostate cancer.N Engl J Med. 2020; 382: 2091-2102
- Colorectal cancer statistics, 2020.CA Cancer J Clin. 2020; 70: 145-164
- AGA technical review on hereditary colorectal cancer and genetic testing.Gastroenterology. 2001; 121: 198-213
- Racial and ethnic disparities in germline genetic testing of patients with young-onset colorectal cancer.Clin Gastroenterol Hepatol. 2020 Dec 24; S1542-3565: 31721-31723https://doi.org/10.1016/j.cgh.2020.12.025
- Disparities in genetic testing: thinking outside the BRCA box.J Clin Oncol. 2006; 24: 2197-2203
- Racial variation in frequency and phenotypes of APC and MUTYH mutations in 6,169 individuals undergoing genetic testing.Genet Med. 2015; 17: 815-821
- Breast cancer screening in women at higher-than-average risk: recommendations from the ACR.J Am Coll Radiol. 2018; 15: 408-414
- Early cancer diagnoses through BRCA1/2 screening of unselected adult biobank participants.Genet Med. 2018; 20: 554-558
- Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications.Breast Cancer Res Treat. 2017; 164: 263-284
- Preventing ovarian cancer through genetic testing: a population-based study.Clin Genet. 2014; 86: 496-499
- Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle?.J Clin Oncol. 2018; 37: 453-460
- Assessing the effectiveness of the National Comprehensive Cancer Network genetic testing guidelines in identifying African American breast cancer patients with deleterious genetic mutations.Breast Cancer Res Treat. 2019; 178: 151-159
- Projecting the supply and demand for certified genetic counselors: a workforce study.J Genet Couns. 2018; 27: 16-20
- Impact of payer constraints on access to genetic testing.J Oncol Pract. 2017; 13: e47-e56
- Barriers and facilitators to genetic service delivery models: scoping review.Interact J Med Res. 2021; 10: e23523
- All syndromes known to man evaluator.(Available at:)www.ask2me.org(Accessed August 13, 2018)Date: 2018
- Role of genomics in eliminating health disparities.J Carcinog. 2015; 14: 6
- Disparities in genetic testing and care among black women with hereditary breast cancer.Curr Breast Cancer Rep. 2020; 12: 125-131
- Breast cancer screening recommendations: African American women are at a disadvantage.J Breast Imaging. 2020; 2: 416-421
- Public attitudes towards genetic testing revisited: comparing opinions between 2002 and 2010.Eur J Hum Genet. 2013; 21: 793-799
- Towards a more inclusive and dynamic understanding of medical mistrust informed by science.Behav Med. 2019; 45: 79-85
- A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients.Genet Med. 2020; 22: 407-415
- Associations between cancer predisposition testing panel genes and breast cancer.JAMA Oncol. 2017 Sep 1; 3: 1190-1196https://doi.org/10.1001/jamaoncol.2017.0424
- A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.Cancer. 2017; 123: 1721-1730
- Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.Cancer. 2015; 121: 25-33
- Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment.JAMA Oncol. 2015; 1: 943-951
Article info
Publication history
Published online: October 18, 2021
Identification
Copyright
© 2021 Elsevier Inc. All rights reserved.
